Related Experiment Video
Updated: Aug 8, 2026
09:47
Isolation, Processing and Analysis of Murine Gingival Cells
Published on: July 2, 2013
Blocking periodontal disease progression with anti-inflammatory agents
1Department of Periodontology, Harvard School of Dental Medicine, Boston, MA.
Journal of Periodontology
|August 1, 1993
Summary
Non-steroidal anti-inflammatory drugs (NSAIDs) show potential in managing periodontal disease by inhibiting prostaglandins, key mediators of inflammation. Research over 20 years explored NSAIDs' effects on gingival inflammation and bone loss.
Area of Science:
- Periodontology
- Immunology
- Pharmacology
Background:
- Periodontal disease involves specific immuno-inflammatory pathways.
- Prostaglandins are key mediators in these inflammatory responses.
- Non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit prostaglandin action.
Purpose of the Study:
- To review research on NSAIDs' effects on periodontal disease progression.
- To explore the modulation of host responses in periodontal disease.
Main Methods:
- Systematic review of studies published over the last two decades.
- Analysis of research investigating NSAID efficacy in periodontal disease models.
Main Results:
- NSAIDs were explored for their impact on gingival inflammation.
- The effect of NSAIDs on alveolar bone loss was investigated.
Conclusions:
- NSAIDs represent a potential therapeutic strategy for periodontal disease.
- Modulating prostaglandin pathways with NSAIDs may slow disease progression.
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:27The Oral Microbiota
The oral microbiome includes a complex ecosystem comprising over 700 microbial species, identified through genomic sequencing and culture-based analyses to date. This community includes a core microbiome, found universally among individuals, and a variable component influenced by environmental factors such as diet, lifestyle, and host genetics. Site-specific conditions, including oxygen gradients, pH levels, and nutrient availability, determine the spatial distribution of these microorganisms...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...